Uvimag B6 is used in situations involving certain distressing symptoms that arise from an established magnesium deficiency and an associated Vitamin B6 deficit. The preparation is applied in contexts where additional symptomatic support is needed and is relevant for cases where short-term symptom management is appropriate.

---

Supporting Neuromuscular Comfort and Reducing Spasm Patterns

This domain is relevant for easing symptoms of increased neurological or muscular activity, which includes involuntary muscle cramps, spasms, and twitches. Applied in scenarios where additional management of discomfort is required, the preparation provides supportive relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.

---

Easing Physical and Emotional Manifestations of Severe Stress

The combination is commonly used across conditions presenting with heightened physiological stress, offering supportive relief for symptoms related to systemic imbalance, such as persistent fatigue, generalized weakness, and related mood fluctuations in deficient individuals. This supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.

---

Targeted Relief in Specific Clinical Scenarios

This use is applicable in conditions characterized by periods of episodic or fluctuating manifestations. The Pyridoxine component is relevant for easing challenging gastrointestinal symptoms, commonly used to help with mild to moderate nausea and vomiting during pregnancy. The combination may also assist in managing certain physical symptoms associated with Premenstrual Syndrome (PMS).

---

Quick Fact

Quick Fact: Symptoms of Increased Neurological Activity

This use is applicable in scenarios where additional management of discomfort is required, applied when symptoms create noticeable functional strain.

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia

Eligibility Map: Who can and cannot use Uvimag B6 — official regulatory information

The regulatory eligibility profile for Uvimag B6 is defined by official documents that specify population groups allowed to use the medicine, those for whom use is restricted, and those for whom use is strictly prohibited.

Eligibility Scope

Category	Regulatory Status	Restrictions
Standard Use	Permitted	Adults and Older Adults with established magnesium deficiency; Breastfeeding women; Patients with mild to moderate renal impairment.
Contraindicated	Prohibited (Absolute)	Patients with Severe Renal Impairment (GFR below 30 ml/min); Patients with known Hypersensitivity to ingredients; Patients with Hyperphosphataemia (due to phosphate content).
Conditional Use	Restricted	Pregnancy (only if benefits outweigh risks, as safety is not fully established); Children and Adolescents (4–18 years, requires physician supervision).
Not Recommended	Limited Data	Children below 4 years of age (due to insufficient clinical data).

Eligibility Classifications

Official regulatory documents classify use based on the level of safety assessment and physiological constraints.

• Eligibility Severity Classification: Contraindicated (Absolute Prohibition), Not Recommended (Insufficient Data), Conditional Use (Risk/Benefit Assessment), and Permitted (Standard Use).
• Eligibility-Context Constraints: Organ function (Renal impairment), Comorbidity (Hyperphosphataemia), Age (Pediatric data), and Reproductive status (Pregnancy/Lactation).

Connection to the overall eligibility profile: Regulatory documents define the eligibility profile by establishing strict physiological and age-based limitations. Contraindications create absolute non-eligibility thresholds, while conditional status applies to populations like pregnant women and children aged 4 to 18, requiring specific oversight for use.

The official interaction profile for Uvimag B6 (Magnesium Glycerophosphate and Pyridoxine Hydrochloride) documents specific pharmacokinetic and pharmacodynamic constraints with other medicinal products.

Pharmacokinetic Interactions and Timing Rules

Magnesium salts cause chelation, which reduces the systemic exposure of certain antibiotics, including Tetracyclines and Fluoroquinolones. Regulatory requirements dictate a mandatory timing separation of two to four hours between the administration of the magnesium component and these antibiotics to ensure proper absorption.

The Pyridoxine component is documented to interfere with the metabolism of anticonvulsants such as Phenytoin and Phenobarbital, decreasing their plasma concentration and potentially reducing their efficacy. An officially recognized interaction also exists with Levodopa, where Pyridoxine accelerates its breakdown, though this is minimized when co-administered with a decarboxylase inhibitor.

Pharmacodynamic Risks and Restrictions

Pharmacodynamic risks include additive central nervous system effects with other CNS depressants. A formal contraindication is documented for co-administration with Monoamine Oxidase (MAO) Inhibitors in specific Pyridoxine-containing combination product labels. Additionally, patients with renal impairment have a documented risk of elevated serum magnesium concentration due to reduced renal clearance.

Uvimag B6 combines Magnesium and Pyridoxine (Vitamin B6), and its mechanism of action centers on two distinct yet complementary physiological pathways which influence specific biological activity.

Cofactor and Enzymatic Catalysis

This domain covers the role of Pyridoxine's active form (Pyridoxal 5-Phosphate or PLP) as a vital coenzyme for over 100 enzymatic reactions, primarily in amino acid metabolism and neurotransmitter synthesis. By participating in these key molecular steps, it supports the proper creation of crucial mediators like GABA and serotonin, resulting in modulation of specific signaling pathways which influences neurobiological activity.

---

Neurotransmission and Muscular Regulation

This block highlights the role of Magnesium as the second most abundant intracellular cation, which acts to reduce nerve excitability and neuromuscular transmission. It functions as an essential cofactor for numerous enzymes involved in ATP metabolism and cellular energy production. Magnesium's action reduces the membrane potential required for excitation, which modifies nerve and muscle function parameters.

---

Facilitation of Cellular Uptake

This mechanistic domain describes the synergistic effect where Pyridoxine acts to improve the intestinal absorption and subsequent cellular uptake of Magnesium. This action ensures a facilitated engagement of the primary mechanism, relevant in systems utilizing these pathways and modulating the downstream effects of excessive mediator activity.

How Uvimag B6 is Used

This section outlines the usage principles for Uvimag B6 (Magnesium Glycerophosphate and Pyridoxine Hydrochloride).

---

Administration Guidelines

Uvimag B6 is prepared as an oral solution and is administered via the oral route. The medication is reserved for use in adults and is not indicated for the pediatric population. The standard regimen for adults involves a total daily dose of 2 to 3 ampoules.

Standard instructions for the preparation specify that the total daily dose must be divided into 2 or 3 separate intakes throughout the day. For proper administration, the contents of the ampoule must be diluted in a small amount of water prior to ingestion. Each diluted dose should be taken during a meal to meet the contextual requirements for use.

---

Treatment Course and Constraints

The established course of therapy for Uvimag B6 is duration-limited. The initial treatment course should not be prolonged beyond one month unless a medical reassessment is performed. This structures the use of the preparation as a short-term intervention. Additionally, attention must be given to patients with moderate renal impairment as a usage constraint. This constraint is in place to minimize the risk of mineral accumulation in this population.

---

Summary of Use

These guidelines establish a protocol that includes specific preparation (dilution), timing (with meals), and dosage division to ensure correct administration of the oral solution. The use is constrained by an explicit duration limit and is exclusively for adult patients.

Evidence for Addressing Established Magnesium Deficiency and Associated Stress

Research has explored the combination of Magnesium and Pyridoxine in adults who had low measured magnesium levels (low magnesemia) and were experiencing self-reported subjective stress. The evidence base primarily involves short-term Randomized Controlled Trials (RCTs) that monitored changes in standardized stress, anxiety, and depression scores, as well as shifts in biochemical measures related to magnesium status.

The findings describe patterns observed in the studies where participants reported changes in their self-assessed stress and related scores over the study period. These changes was associated with the combination, particularly in the subgroup of people reporting the highest initial levels of stress. The evidence contributes to understanding symptom patterns in deficient individuals, suggesting that the preparation was observed in some studies where measured changes were recorded in these outcomes.

However, the follow-up durations were limited, typically lasting only about eight weeks. This means that long-term effects are not fully established. Furthermore, the comparative evidence is lacking in some areas, as findings were mixed regarding whether the inclusion of the Pyridoxine component provided a distinct, measurable difference over taking Magnesium alone across all measured outcomes and study populations.

---

Research Gaps and Areas of Uncertainty

The research highlights what is known—and what is still uncertain about the combination. Certainty remains low concerning the precise added role of the Pyridoxine component in all populations; findings were mixed on whether the combination appears to deliver consistently different results than Magnesium alone across all measures. Additionally, the comparative evidence is lacking for many specific clinical scenarios and in special populations, meaning research is ongoing to fully understand the product's place in the broader evidence landscape.

Common questions about Uvimag B6 (FAQ)

Q: Is Uvimag B6 the same as taking a regular B6 supplement?

According to official product information, Uvimag B6 is classified as a combination product. It contains both Magnesium Glycerophosphate and Pyridoxine Hydrochloride (Vitamin B6). The official purpose of this specific formulation is defined as addressing established magnesium deficiency, which distinguishes it from a single-entity Vitamin B6 supplement.

Q: Can Uvimag B6 cause problems with sleep or insomnia?

Insomnia is not explicitly listed as a common side effect in the documented safety profile. However, regulatory labels for some B-vitamin products have noted that the medication may potentially cause wakefulness or alertness. For this reason, official patient information sometimes suggests administration earlier in the day.

Q: Does Uvimag B6 contain lactose or gluten?

The official composition lists the active ingredients, which are Magnesium Glycerophosphate and Pyridoxine Hydrochloride. To confirm the presence or absence of excipients (inactive components) such as lactose or gluten, the complete list of components in the Patient Information Leaflet or Summary of Product Characteristics must be consulted, as excipients can vary by formulation.

Q: Can Uvimag B6 be taken alongside multivitamins?

Official safety information for products containing Pyridoxine (Vitamin B6) often advises against concurrent use of other products that also contain Vitamin B6. This warning is related to the regulatory rationale for preventing excessive intake, as high levels of Pyridoxine are associated with a risk of sensory neuropathy (nerve tingling).

Q: What is the difference in Uvimag B6 for adults versus children?

The standard daily regimen detailed in official administration guidelines is specifically for adults. For children and adolescents aged 4 to 18 years, use is classified as conditional. This means the adult regimen is not indicated for this group, and use requires the supervision of a healthcare professional to determine appropriate usage.

Q: Is Uvimag B6 a prescription drug or available over-the-counter?

The legal classification of the product (whether it is available over-the-counter or requires a prescription) is set by the specific national regulatory authority. This status is not universally consistent and can vary by country based on local regulations and the dosage strength of the preparation.

Q: Are there any common misuses of Uvimag B6 that people should know about?

Official warnings note the potential consequences of exceeding the recommended duration of use. The risk of sensory neuropathy (tingling or numbness) is associated with the long-term use of high-dose Pyridoxine. Exceeding the one-month duration limit without medical reassessment, as specified in the official course of therapy, increases this risk.

Q: What should someone do if they miss a dose of Uvimag B6?

Official patient instructions advise that if a dose is forgotten, the next dose should be taken at the usual scheduled time. Official patient information states that a double dose should not be taken to compensate for a forgotten dose.

Q: Is there any research evidence supporting the use of Uvimag B6 for stress?

Research evidence exists from short-term trials that have examined the combination in adults who had existing low magnesium levels (low magnesemia) and were experiencing high self-reported subjective stress. These studies documented observed changes in self-assessed stress and related scores in this specific subgroup of individuals.

Q: Why do some people experience tingling sensations when taking B6?

The tingling sensation, known as sensory neuropathy, is officially linked to the long-term use of high-dose Pyridoxine. This adverse reaction is thought to occur due to the potential disruption of normal function in the peripheral nervous system pathways.

Q: What is the difference between Uvimag B6 and similar products containing only magnesium?

The Pyridoxine component is defined as having a synergistic role by officially supporting the intestinal absorption and subsequent cellular uptake and retention of Magnesium. Research has explored whether this provides a measurable difference over taking Magnesium alone, and the combination utilizes this synergistic mechanism as its formulation rationale.

Q: Does Uvimag B6 affect mood or anxiety levels, according to studies?

Research studies that examined the combination in individuals with low magnesemia and stress monitored standardized anxiety and depression scores. Findings from these short-term trials documented observed changes in these scores over the study period.

Q: Is Uvimag B6 primarily focused on treating B6 deficiency?

Official documents define the general purpose as addressing states of established magnesium deficiency, whether it is isolated or associated with a concurrent Vitamin B6 deficit. This confirms that the primary focus of the combination product is on replenishing the core mineral component.

How to Store and Dispose of Uvimag B6

The storage and disposal of Uvimag B6 oral solution must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Maximum Temperature	Store at a temperature not exceeding 30 C
Environmental Protection	Store in a dry place
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Uvimag B6 is provided in single-dose ampoules intended for immediate use. Any unused or expired medicinal product, including residual waste material, must be disposed of in accordance with local regulations for pharmaceutical waste. Consult a pharmacist or local waste management authority for specific instructions on disposal procedures.